Effect Of Type And Dosage Of Newly Prescribed Inhaled Corticosteroids On Obstructive Lung Disease And Pneumonia Hospitalisations In Older Individuals With Asthma, Copd Or Both: A Retrospective Study Of Health Administrative Data

The safety and risk-benefit profiles associated with different types and dosages of inhaled corticosteroids (ICS) in older individuals with asthma and COPD remain unknown [1, 2]. Limited evidence suggests that adults with asthma prescribed medium or high ICS doses are at risk of clinically important systemic side effects that do not plateau with higher doses as efficacy outcomes do [3]. Older patients with COPD have been shown to have increased risk of pneumonia with both budesonide and fluticasone [4]; however, the risk seems greater in the latter [2, 4–6].\n\nFootnotes \n\nThis manuscript has recently been accepted for publication in the European Respiratory Journal . It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.\n\nConflict of interest: Dr. Kendzerska reports grants from Canadian Respiratory Research Network , during the conduct of the study;.\n\nConflict of interest: Dr. Aaron has nothing to disclose.\n\nConflict of interest: Dr. To has nothing to disclose.\n\nConflict of interest: Dr. Licskai has nothing to disclose.\n\nConflict of interest: Dr. Stanbrook has nothing to disclose.\n\nConflict of interest: Dr. Hogan has nothing to disclose.\n\nConflict of interest: Dr. Tan has nothing to disclose.\n\nConflict of interest: Dr. Bourbeau has nothing to disclose.\n\nConflict of interest: Dr. Gershon reports grants from Canadian Respiratory Research Network , grants from Health Systems Research Fund Capacity Grant, Government of Ontario, during the conduct of the study.